Financial Daily from THE HINDU group of publications
Friday, May 26, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Corporate - Mergers & Acquisitions


Acquisitions on the radar for Ranbaxy's promoter-scions

P.T. Jyothi Datta

Focus on consolidation; Fortis looks at inorganic growth


EYING BUYS: (From right) Mr Malvinder M. Singh, Chairman, Religare and CEO & MD, Ranbaxy Laboratories, with Mr Sunil Godhwani, CEO & Managing Director, Religare, and Mr Shivinder M. Singh, Director, Religare and MD, Fortis Healthcare, at a press conference in Mumbai on Thursday. — Paul Noronha

Mumbai , May 25

After three overseas acquisitions on a trot in March, one would think home-spun drug-maker Ranbaxy's appetite for the same would be a little satiated. But it does not seem so, with both brothers of the Ranbaxy-promoter family having acquisitions on their mind in their respective businesses.

"This is not the end," Mr Malvinder Mohan Singh, Chief Executive Officer and Managing Director of Ranbaxy Laboratories told Business Line, indicating that acquisition-plans were alive in Europe, the United States and India.

Consolidation

Consolidation is on the cards, he said, adding that it was "way overdue" in India. There were several "soft" reasons for acquisitions not happening in the domestic market, including the fact that some companies were family-run, he observed.

However, he added, one trigger would set the process on the roll, as seen in markets overseas.

In just one week in March, Ranbaxy acquired Belgium's Ethimed NV, GlaxoSmithKline's generic business Allen SpA of Italy and Terapia in Romania.

Ranbaxy has got a green signal for an enabling resolution to raise up to $1.5 billion through appropriate securities and had raised $440 million through the foreign currency convertible bonds (FCCBs).

Inorganic growth is one of the strategies that younger brother Mr Shivinder Mohan Singh, too, would adopt to grow the Fortis network of hospitals across the country.

The junior Mr Singh is Managing Director of Fortis Healthcare, promoted by the Ranbaxy-family.

National footprint

Fortis has a strong foot-hold in the northern region, with about 12 hospitals. But the healthcare company looks to establish a national footprint, Mr Shivinder Singh told this correspondent.

Three more hospitals are slated for the year, he said and added they could be in locations across the country.

Mumbai, considered to be a real-estate nightmare for companies harbouring retail plans, is also on the radar, eventually, he said. Fortis has had interactions with private equity investors, he admitted, unwilling to get into specifics.

More Stories on : Pharmaceuticals | Mergers & Acquisitions | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Monsoon onset over Kerala, North-east likely tomorrow


Decision likely on petro price revision next week
No extension for Subir Raha
Acquisitions on the radar for Ranbaxy's promoter-scions
PMO initiates move to unbundle BSNL's network for broadband
States to seek higher share of VAT pie
Oil bonds boost HPCL Q4 net four-fold
L&T Q4 net profit jumps 40%
Hangovers cost Bangalore corporates Rs 47 cr
Dell manufacturing facility to be operational by year-end
Dedicated TCS centre for banking services solutions
Sensex recovers as margins ease
KVB announces 1:1 bonus, 1:2 rights



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line